



NATCO Pharma Limited

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034.
Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2018

(₹ in millions except per share data)

	Quarter ended			Year ended
	30 Jun 2018 (Unaudited)	31 March 2018 (Refer note 6)	30 Jun 2017 (Unaudited)	31 Mar 2018 (Audited)
Revenue				
Revenue from operations (Refer note 5)	5,386	7,678	4,453	22,020
Other income	359	201	34	404
Total revenues	5,745	7,879	4,487	22,424
Expenses				
Cost of materials consumed	888	1,075	1,286	3,905
Excise duty (Refer note 5)	-	-	172	172
Purchases of stock-in-trade	111	35	256	459
Changes in inventories of finished goods, Stock-in - Trade and work-in-progress	(126)	120	(448)	(253)
Employee benefits expense	887	1,101	631	3,256
Finance costs	28	30	39	154
Depreciation and amortisation expense	184	180	150	662
Other expenses	1,450	1,514	1,189	5,197
Total expenses	3,422	4,055	3,275	13,552
Profit before tax	2,323	3,824	1,212	8,872
Tax expense / (credit)				
Current tax	648	1,108	266	2,199
Deferred tax	(136)	(281)	9	(279)
Profit after tax	1,811	2,997	937	6,952
Other comprehensive income (net of taxes)				
Items that will not be reclassified to profit or loss				
Re-measurement gains/(losses) on defined benefit plans	(11)	(35)	(8)	(42)
Net (loss)/gain on FVTOCI equity securities	2	(2)	7	(2)
Items that will be reclassified to profit or loss				
Exchange differences on translation of foreign operations	22	(42)	38	(8)
Total comprehensive income	1,824	2,918	974	6,900
Profit attributable to:				
Owners of the parent	1,816	2,999	940	6,962
Non-controlling interests	(5)	(2)	(3)	(10)
Total comprehensive income attributable to:				
Owners of the parent	1,829	2,920	977	6,910
Non-controlling interests	(5)	(2)	(3)	(10)
Paid-up equity share capital of ₹2 each	369	369	349	369
Other equity (Revaluation reserve ₹Nil)				30,353
Earnings per share (non-annualised) (face value of ₹2 each)				
Basic (in ₹)	9.84	16.26	5.59	39.26
Diluted (in ₹)	9.82	16.21	5.58	39.13



NATCO Pharma Limited

Notes to the consolidated results:

1. The consolidated financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India.
2. The consolidated financial results for the quarter ended 30 June 2018 have been reviewed by the Audit Committee of the board and approved by the Board of Directors of the Company at their meeting held on 8 August 2018.
3. The Group operates in one reportable segment which is "Pharmaceuticals".
4. Excise duty on sales was included under Revenue from operations and disclosed separately under expenses upto all reporting periods ending 30 June 2017. Post implementation of Goods and Services Tax (GST) from beginning of the quarter ended 30 September 2017, revenue from operations is reported net of GST and hence to that extent is not comparable.
5. The figures of the quarter ended 31 March 2018 are the balancing figures between audited figures in respect of full financial year ended 31 March 2018 and the unaudited published year to date figures upto 31 December 2017 which were subjected to limited review.
6. On the basis of future business plans and the impact thereof on the future taxable income, the management, at present, believes that the Company would continue to pay tax under the Minimum Alternate Tax (MAT) provisions of the Income Tax Act, 1961 from financial year 2019-20. Accordingly, MAT credit, disclosed as a part of deferred tax, is recognized only to the extent of expected utilization.
7. The Board of directors at their meeting held on 8 August 2018 have approved an interim dividend of ₹1.50 per equity share of ₹2 each.

By Order of the Board

A handwritten signature in black ink, appearing to read "V.C. Nannapaneni", written over a faint blue horizontal line.

Hyderabad
8 August 2018

V.C. Nannapaneni
Chairman and Managing Director



NATCO Pharma Limited

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034
Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2018

(₹ in millions except per share data)

	Quarter ended			Year ended
	30 June 2018 (Unaudited)	31 March 2018 (Refer note 3)	30 June 2017 (Unaudited)	31 Mar 2018 (Audited)
Revenue				
Revenue from operations (Refer note 4)	5,157	7,290	4,308	21,085
Other income	357	206	27	394
Total revenues	5,514	7,496	4,335	21,479
Expenses				
Cost of materials consumed	888	1,075	1,286	3,905
Excise duty (Refer note 4)	-	-	172	172
Purchases of stock-in-trade	3	21	187	227
Changes in inventories of finished goods, stock-in-trade and work-in-progress	(90)	92	(447)	(247)
Employee benefits expenses	852	1,060	603	3,122
Finance costs	27	27	38	147
Depreciation and amortisation expense	183	178	148	655
Other expenses	1,253	1,279	1,101	4,622
Total expenses	3,116	3,732	3,088	12,603
Profit before tax	2,398	3,764	1,247	8,876
Tax expense / (credit)				
Current tax	648	1,082	266	2,173
Deferred tax	(136)	(279)	7	(279)
Profit after tax	1,886	2,961	974	6,982
Other comprehensive income (net of taxes)				
Items that will not be reclassified to profit or loss				
Re-measurement gains/(losses) on defined benefit plans	(11)	(35)	(8)	(42)
Net gain/(loss) on FVTOCI equity securities	1	(5)	6	(5)
Total comprehensive income	1,876	2,921	972	6,935
Paid-up equity share capital of ₹2 each	369	369	349	369
Other equity (Revaluation reserve ₹Nil)				30,885
Earnings per share (non-annualised) (face value ₹2 each)				
Basic (in ₹)	10.22	16.05	5.58	39.38
Diluted (in ₹)	10.19	16.01	5.56	39.24



NATCO Pharma Limited

Notes to the standalone results:

1. The standalone financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India.
2. The standalone financial results for the quarter ended 30 June 2018 have been reviewed by the Audit Committee of the board and approved by the Board of Directors of the Company at their meeting held on 8 August 2018.
3. The figures of the quarter ended 31 March 2018 are the balancing figures between audited figures in respect of full financial year ended 31 March 2018 and the unaudited published year to date figures upto 31 December 2017 which were subjected to limited review.
4. Excise duty on sales was included under Revenue from operations and disclosed separately under expenses upto all reporting periods ending 30 June 2017. Post implementation of Goods and Services Tax (GST) from beginning of the quarter ended 30 September 2017, revenue from operations is reported net of GST and hence to that extent is not comparable.
5. The Company operates in one reportable segment which is "Pharmaceuticals".
6. On the basis of future business plans and the impact thereof on the future taxable income, the management, at present, believes that the Company would continue to pay tax under the Minimum Alternate Tax (MAT) provisions of the Income Tax Act, 1961 from financial year 2019-20. Accordingly, MAT credit, disclosed as a part of deferred tax, is recognized only to the extent of expected utilization.
7. The Board of directors at their meeting held on 8 August 2018 have approved an interim dividend of ₹1.50 per equity share of ₹2 each.

By Order of the Board

A handwritten signature in black ink, appearing to read "V.C. Nannapaneni", written over a horizontal line.

Hyderabad
8 August 2018

V.C. Nannapaneni
Chairman and Managing Director